NCT07385235 Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'
| NCT ID | NCT07385235 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Addpharma Inc. |
| Condition | Gastric Ulcer |
| Study Type | INTERVENTIONAL |
| Enrollment | 46 participants |
| Start Date | 2026-01-27 |
| Primary Completion | 2026-03-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 46 participants in total. It began in 2026-01-27 with a primary completion date of 2026-03-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study compare and evaluate the safety and pharmacokinetic characteristics of a single dose administration of 'AD-115A' or 'AD-1151' in healthy adults.
Eligibility Criteria
Inclusion Criteria: * The Age equal to or greater than 19 in healthy volunteers at the time of screening visit * Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit Exclusion Criteria: * Individuals who have taken drugs that induce (e.g., barbiturates) or inhibit drug-metabolizing enzymes within 30 days prior to the start of the study (first dosing day), or have taken drugs that may affect this study within 10 days prior to the start of the study (first dosing day) * Other exclusions applied
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07385235 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Gastric Ulcer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07385235 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07385235 currently recruiting?
Yes, NCT07385235 is actively recruiting participants. Contact the research team at jhjung@addpharma.co.kr for enrollment information.
Where is the NCT07385235 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07385235 clinical trial?
NCT07385235 is sponsored by Addpharma Inc.. The trial plans to enroll 46 participants.